Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ketamine for Postherpetic Neuralgia With Depression
Sponsor: Huazhong University of Science and Technology
Summary
This clinical trial examines the antidepressant efficacy and safety of a single low-dose intravenous esketamine combined with oral duloxetine in patients with postherpetic neuralgia and depression (duration more than 1 month). In this prospective, randomized, double-blind, placebo-controlled parallel study, eligible patients were randomized into two groups: one received esketamine plus duloxetine, and the other got placebo plus duloxetine. Both groups underwent standard pain management and neuro modulation therapy. The primary outcome was the Hospital Anxiety and Depression Scale - Depression( HADS-D)score at 2 weeks post - infusion, with various secondary outcomes assessed over multiple time points. Data were collected through in-person interviews and telephone follow-ups.
Official title: "Efficacy and Safety of Single Low-Dose Intravenous Ketamine for Postherpetic Neuralgia With Depression: A Randomized Controlled Study
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-06-15
Completion Date
2026-06-01
Last Updated
2025-06-03
Healthy Volunteers
No
Conditions
Interventions
Intravenous Ketamine Infusions
The patients received a single intravenous infusion of esketamine (0.2 mg/kg), which was added to 50 ml of normal saline and administered via a micro-infusion pump over 40 minutes.
Intravenous normal saline
The patients received a single intravenous infusion of 50 ml normal saline via a micro-infusion pump over 40 minutes
Oral Duloxetine 60mg
Patients received 60 mg/day of oral duloxetine as maintenance therapy for depression.